UP421 demonstrates first human proof of insulin-producing islet cells surviving without immunosuppression

Sana Biotechnology/UP421

NEJM published findings from an investigator-sponsored trial showing that Sana's HIP-modified donor islet cells survived, evaded immune detection, and produced insulin for 12 weeks in a type 1 diabetes patient without any immunosuppressive medications. The transplanted cells demonstrated safe engraftment with appropriate insulin secretion in response to meals.

• First human evidence of allogeneic islet cell transplant surviving and functioning without immunosuppression
• HIP-modified donor islet cells transplanted intramuscularly into forearm
• C-peptide detected and elevated with mixed meal tolerance testing, indicating insulin production
• Patient demonstrated improved glucose control with reduced insulin dependence
• No serious adverse events or safety concerns identified during follow-up